Skip to content

Generic selectors
Correspondance exacte uniquement
Recherche dans le titre
Rechercher dans le contenu
Post Type Selectors
ELA International
ELA International
Secondary Navigation Menu
Menu
  • News
    • Archives News
  • Missions
    • Research funding
    • Support the families
    • To raise public awareness
    • International development
  • Organization
    • Our values
    • Our history
    • Our organization
    • ELA international’s members
    • The members
    • Advisory Board
  • Leukodystrophies
    • Introduction
    • Diseases
      • ALD/AMN
      • Undefined leukodystrophies
      • Canavan disease
      • Krabbe disease
      • Refsum disease
      • Alexander disease
      • MLC disease
      • MLD
      • PMD and other hypomyelinating leukodystrophies
      • Aicardi-Goutières syndrome
      • CACH syndrome
      • LTBL
    • The expert centers
      • Reference Center for Neurogenetic Diseases in Children and Adults
      • Reference Centre for Leukodystrophies in Robert-Debré
      • Reference Center for Leukodystrophies in Bicêtre
    • Make the expert centers known
  • Research
    • Scientific Committee
    • ELA Team
    • Main steps
    • Annual Call for Proposals
    • Clinical Trial FOA
    • Funded Research Projects
    • Clinical Studies
    • Leuconnect
      • Leuconnect
      • Studies online
      • Découvrez la messagerie de Leuconnect
    • Scientific events
      • Families/Researchers Meeting
      • Symposium
    • European Joint Programme on Rare Diseases (EJP Rare Diseases)
    • Additional documentation
    • Partners
  • Support
    • Become a donor
    • Mobilise
    • They support us
    • Become partner
    • Online shop
    • Contact
  • Français
  • English (UK)

USA

For the first time, a boy receives a commercially available gene therapy for cerebral X-linked adrenoleukodystrophy (ALD) in the United States

2023-05-11

On March 16th, 2023, after thirty years of research started in France with the support of ELA, the first boy in the world received the FDA approved gene therapy for the cerebral form of adrenoleukodystrophy. Following a positive newborn screening, 6-year-olds Conner Hess from New York was followed closely toRead More →

© ELA 2022